How innovators and investors are working with patients and providers to develop dynamic new solutions and create healthy returns.
CNBC presents a one-day event that brings together top health care investors, CEOs and technologists to explore the innovations that will drive better outcomes, financially and clinically.
Every health care company seeks to scale the best technology and develop profitable ways to cover the massive cost of research and development, investors are looking for actionable intelligence on who’s breaking through, and patients are hungry for affordable and effective care. Healthy Returns is a convening of leaders who are improving patient outcomes, maximizing innovation, building great new companies and reinventing incumbents.
Led by CNBC’s anchors and reporters, Healthy Returns hones in on groundbreaking ideas that will transform the health care industry, cutting through the noise and weeding out the “sales pitch.”
Who should attend:
Health care investors, VCs, C-Suite executives from the biotech, pharma, health care and life sciences industries, health care IT BDMs.
Martine Rothblatt is Chairman & CEO of United Therapeutics, a biotechnology company she started to save the life of one of her daughters. The company offers FDA approved medicines for pulmonary hypertension and neuroblastoma and is working on manufacturing an unlimited supply of transplantable organs.
Dr. Rothblatt previously created and led Sirius XM as its Chairman & CEO, and launched other satellite systems for navigation and international television broadcasting. In the field of aviation her Sirius XM satellite system enhances safety with real-time digital weather information to pilots in flight nationwide. She also designed the world’s first electric helicopter, which in 2018 set Guinness world records for distance and flight duration.
In the legal arena, Dr. Rothblatt led efforts to create transgender health law standards, and to protect privacy and autonomy rights in genetic information via an international treaty. She has Bachelor’s (Communications Studies, Summa Cum Laude), JD and MBA degrees from UCLA, and a Ph.D. in Medical Ethics from the Royal London School of Medicine & Dentistry. Her patented inventions cover aspects of satellite radio, prostacyclin biochemistry and cognitive software. Dr. Rothblatt’s recent books are on xenotransplantation (Your Life or Mine), non-binary gender identity (Transgender to Transhuman) and cyberethics (Virtually Human).
Alex Gorsky is Chairman of the Board and Chief Executive Officer of Johnson & Johnson and Chairman of the Executive Committee, the Company’s senior leadership team. Alex is the seventh person to serve as Chairman and CEO of Johnson & Johnson since it became a publicly traded company in 1944.
Alex began his Johnson & Johnson career as a sales representative with Janssen Pharmaceutica in 1988. Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing and management including assignments in the U.S., Europe, Africa and the Middle East. He progressed through many management posts at J&J, culminating in being named Chief Executive Officer on April 26, 2012 and Chairman of the Board on December 28, 2012.
Under Alex Gorsky’s leadership, Johnson & Johnson continues in its 132nd year to be one of the world’s exceptional corporations. The company was given the #1 ranking on Barron’s Magazine’s 2016 list of the “World’s Most Admired Companies,” and is currently the number one Pharmaceutical company on Fortune Magazine’s list of the “World’s Most Respected Companies.
A longtime advocate of Diversity Inclusion and Veteran’s issues, Alex has been named one of the “100 Most Inspiring Leaders” by Pharma Voice. Most recently, in December of 2017, Alex received the Ripple of Hope Award from the Robert F. Kennedy Human Rights Foundation. And for the past three years, Alex has been on the list of the Highest Rated CEOs on The Glassdoor Employees’ Choice Awards. He has also received the Jackie Robinson Award, Appeal of Conscience Award, the Joseph Wharton Leadership Award and the CADCA Humanitarian of the Year Award.
Alex is a member of the Board of Directors of IBM, the Wharton School of Business Board of Overseers and the Board of Directors of the Business Roundtable.
Alex holds a Bachelor of Science degree from the U.S. Military Academy at West Point, N.Y., and spent six years in the U.S. Army, finishing his military career with the rank of Captain. Alex earned a Master of Business Administration degree from The Wharton School of the University of Pennsylvania in 1996.
Vasant (Vas) Narasimhan, M.D., has been Chief Executive Officer (CEO) of Novartis since February 1, 2018.
Dr. Narasimhan previously was Global Head of Drug Development and Chief Medical Officer for Novartis. He has also served as Global Head of Development for Novartis Pharmaceuticals, Global Head of the Sandoz Biopharmaceuticals and Oncology Injectables business unit, Global Head of Development for Novartis Vaccines, North America Region Head for Novartis Vaccines, and United States Country President for Novartis Vaccines and Diagnostics. Before joining Novartis in 2005, he worked at McKinsey & Company.
Dr. Narasimhan received his medical degree from Harvard Medical School in the US, a master’s degree in public policy from Harvard’s John F. Kennedy School of Government, and a bachelor’s degree in biological sciences from the University of Chicago in the US. During and after his medical studies, he worked extensively on a range of public health issues in developing countries. He is an elected member of the US National Academy of Medicine and serves on the board of fellows of Harvard Medical School.
Daphne Koller brings to insitro her many years of experience in the areas of machine learning, statistical modeling, computational biology, and computational medicine. She was the Rajeev Motwani Professor of Computer Science at Stanford University, where she was hired as the first machine learning professor in 1995 and served on the faculty for 18 years. Her work in machine learning spans a broad range of topics, including probabilistic graphical models, structured prediction, active learning, time series modeling, reinforcement learning, and many more. She was also one of the pioneers in applying machine learning to biomedical data sets, and has worked on topics such as reconstruction of regulatory networks, phenotypic effects of genetic variation, and interpretation of microscopy images in cancer. She is the author of over 200 refereed publications appearing in diverse venues such as NIPS, ICML, Science, Cell, and Nature Genetics, and has an h-index of over 120. She is also the author of the leading textbook on Probabilistic Graphical Models.
Daphne co-founded Coursera in 2012, where she served as the company’s Co-CEO until 2014, and then as President until 2016. Coursera is the world’s largest online education platform with over 30 million learners worldwide, and over 150 university partners in six continents. She is currently the Co-Chair of the Coursera Board. Most recently, Daphne served as the Chief Computing Officer at Calico Labs, an Alphabet (Google) company that is using advanced technology to understand aging and design interventions that help people lead longer, healthier lives.
Daphne was recognized as one of TIME Magazine’s 100 most influential people in 2012 and Newsweek’s 10 most important people in 2010. She has been honored with multiple awards and fellowships during her career including the Sloan Foundation Faculty Fellowship in 1996, the ONR Young Investigator Award in 1998, the Presidential Early Career Award for Scientists and Engineers (PECASE) in 1999, the IJCAI Computers and Thought Award in 2001, the MacArthur Foundation Fellowship in 2004, and the ACM Prize in Computing in 2008. Daphne was inducted into the National Academy of Engineering in 2011 and elected a fellow of the American Academy of Arts and Sciences in 2014 and of the International Society of Computational Biology in 2017.
Scott Gottlieb, MD is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration. Dr. Gottlieb’s work focuses on advancing public health through developing and implementing innovative approaches to improving medical outcomes, reshaping healthcare delivery, and expanding consumer choice and safety.
Dr. Gottlieb is an aggressive advocate for advancing the health of patients, promoting healthcare access, and driving innovation. The agency’s historic and prolific advances in new policy distinguished his tenure as the FDA’s commissioner, in addition to a record-setting number of approvals of novel drugs, medical devices, and generic medicines.
Under his leadership, the FDA advanced new frameworks for the modern and safe and effective oversight of gene therapies, cell based regenerative medicines, targeted drugs, and digital health devices. The agency implemented new reforms to standardize drug reviews and make historic improvements of post market data collection and the use of real world evidence. He promoted policies to reduce death and disease from tobacco, improve food innovation and safety, and aggressively confront addiction crises.
Previously, Dr. Gottlieb served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and before that, as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services, where he helped advance policies to improve healthcare quality and promote the effective use of new medical technologies. A healthcare futurist, he works as a venture capitalist and has been a founder and board member to companies that have developed new medicines and advance the delivery of healthcare.
Dr. Gottlieb is widely published in leading medical journals and periodicals, including The Wall Street Journal, The New York Times, and The Washington Post. He has held editorial positions on the British Medical Journal and the Journal of the American Medical Association. Fortune Magazine recognized him as one of the “World’s 50 Greatest Leaders” in 2018 and again in 2019. Modern Healthcare named Dr. Gottlieb as one of the “Most Influential Physician Executive and Leaders” in its annual survey of 50 physician executives, and Time magazine named Gottlieb one of its “50 People Transforming Healthcare in 2018.”
Dr. Gottlieb was a practicing hospitalist and a Clinical Assistant Professor at the New York University School of Medicine. He is an elected member of the National Academy of Medicine and a Resident Fellow at the American Enterprise Institute in Washington, DC.
Scarlet is the head of product and platform lead for Project Baseline, Verily's bold initiative to map human health and democratize research. Prior to joining Verily, Scarlet held roles in product, strategy, and business development at a variety of life science and technology companies. Scarlet received her B.A. from the University of Pennsylvania and was a faculty scholar at the NYU Stern School of Business.
Dr. Samarth Kulkarni has served as Chief Executive Officer of CRISPR Therapeutics since December 2017.
He has significant expertise in strategy and operations in biotech and a wide range of related cutting-edge therapeutic technologies. He joined CRISPR in August 2015 in the early stages of the company as Chief Business Officer, and then served as President and Chief Business Officer starting May 2017. Prior to joining CRISPR, Sam was a Partner at McKinsey & Company, where he had a leading role in the Pharmaceutical and Medical products practice. While at McKinsey, he co-led the biotech practice, served a number of biotechnology companies on topics ranging from strategy to operations and led initiatives in areas such as personalized medicine and immunotherapy. Sam also serves as a member of the Casebia Board of Directors.
He received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology. While at the University of Washington, he conducted research in the delivery of biological drugs and in the field of molecular diagnostics. He has authored several publications in leading scientific and business journals.
Dr. Jennifer Schneider is the President of Livongo. In this role, she is responsible for product, data science, engineering, marketing, and clinical operations. Dr. Schneider previously served as the company’s Chief Medical Officer where she led the company’s strategic clinical product vision, data science, clinical trials, and the organization’s certified diabetes educators and coaches.
Prior to Livongo, Dr. Schneider held several key leadership roles at Castlight Health, most recently as Chief Medical Officer. She also has held leadership roles in the provider setting as a health outcomes researcher and Chief Resident at Stanford University, and has practiced medicine as an attending physician at Stanford University, the VA Palo Alto Health Care System, and Kaiser Permanente. Dr. Schneider has an undergraduate degree from the College of the Holy Cross, a Doctor of Medicine degree from Johns Hopkins School of Medicine, and a Master of Science degree in Health Services Research from Stanford University. She completed her internal medicine residency at Stanford University Hospital.
Dr. Schneider is a frequent speaker about innovation in healthcare, where she shares her unique perspective as a practicing physician, health services researcher, senior executive and individual who has lived with Type 1 diabetes for more than 30 years. She has three children and is an avid runner and athlete, having completed her first IronMan in 2016.
David Cordani became president and CEO of Cigna in 2009 and has spearheaded its transformation into a leading global health service company, doubling the size of the company in six years. He is a prominent voice addressing key health challenges, such as the empowering of individuals to manage their own health, innovating new health delivery models focused on patients’ health improvements and partnering with physicians to focus on wellness, and improving clinical quality. With operations and capabilities in more than thirty countries, Cordani leads Cigna’s approximately 43,000 employees in improving the health, well-being and sense of security of more than 95 million customer relationships.
Cordani joined Cigna in 1991; his leadership experiences cross critical disciplines of health care services including distribution, marketing, clinical management, underwriting, finance and operations.
Prior to joining Cigna, Cordani was with Coopers & Lybrand. He actively works with the Achilles International Freedom Team of Wounded Veterans and ChildObesity180, where he is a charter board member. He also supports organizations including March of Dimes and The Juvenile Diabetes Research Foundation. In addition, he is founder of The David and Sherry Cordani Family Foundation, reflecting the Cordani family’s deep commitment to supporting community health and well-being. Cordani was named to the General Mills Board of Directors in 2014 and to the U.S.-India Business Council Board of Directors in 2015.
David Cordani is an accomplished triathlete, having competed in more than 125 triathlons. He earned a bachelor’s degree from Texas A&M, and an MBA from the University of Hartford.
Susan DeVore is CEO of Premier with approximately 30 years of experience. DeVore’s tenure with Premier has centered on driving innovation in healthcare and leading the industry through profound change by engaging stakeholders to co-develop solutions that support high-quality, efficient and sustainable care delivery models.
DeVore is an industry-leading thinker who has consistently been named multiple times to Modern Healthcare's 100 Most Influential People and Top 25 Women in Healthcare lists. She recently received the Charlotte Business Journal’s 2018 Women in Business Lifetime Achievement Award, was named to Becker’s Hospital Review’s 2017 100 Great Healthcare Leaders to Know and was recognized as a 2016 UNC Charlotte Distinguished Alumnus.
DeVore currently serves on the Board of Trustees for the Healthcare Leadership Council; is Board Member of the Coalition to Protect America’s Healthcare; is a Board Member, Finance Committee Member and Audit Committee Chair of the Medicare Rights Center; is a Member of the Charlotte Chamber Executive Committee; is a Member of the Charlotte Executive Leadership Council; and a Member of the UNC Charlotte Board of Trustees. She also serves as a Member of the National Academy of Medicine and the Aspen Health Strategy Group, and most recently joined the Board of Unum Group, a NYSE-listed company, as a Director and Audit Committee Member.
Under DeVore's leadership, Premier has been named as one of the World's Most Ethical Companies for past 11 years, received the Malcolm Baldrige National Quality Award and earned the Best in KLAS title for Overall Healthcare Management Consulting.
DeVore obtained a bachelor’s degree from the University of North Carolina at Charlotte and a Master of Management degree from McGill University.
Jorge Conde is a General Partner at Andreessen Horowitz where he leads investments at the cross section of biology, computer science and health.
Prior to joining a16z, Jorge served as Chief Strategy Officer for Syros (NASDAQ: SYRS), which is advancing a new wave of medicines that control expression of disease-driving genes to treat cancer and other diseases. He previously served as the company's Chief Financial Officer and Chief Product Officer, leading the platform strategy for Syros' novel gene regulation technology. Jorge also cofounded Knome, a human genome interpretation company acquired by Tute Genomics in 2015. Earlier in his career, Jorge worked in marketing and operations at MedImmune and as a biotechnology investment banker at Morgan Stanley.
Jorge holds an MBA from Harvard Business School, an MS from the Harvard-MIT Division of Health Sciences and Technology, and a BA in Biology from Johns Hopkins University.
Jorge was named one of the top 35 young innovators in the world by the MIT Technology Review and is a 2015 Henry Crown Fellow of the Aspen Institute and a member of the Aspen Global Leadership Network. He serves on the board of the Museum of Science, Boston.
Dr. Peter Lee is Corporate Vice President, Microsoft Healthcare. He leads an organization that works on technologies for better and more efficient healthcare, with a special focus on artificial intelligence and cloud computing. Dr. Lee has extensive experience in managing the process of going from basic research to commercial impact. Past illustrative examples include the deep neural networks for simultaneous language translation in Skype, next-generation IoT technologies, and innovative silicon and post-silicon computer architectures for Microsoft’s cloud. He also has a history of advancing more “out of the box” technical efforts, such as experimental under-sea datacenters, augmented-reality experiences for HoloLens and VR devices, digital storage in DNA, and social chatbots such as XiaoIce and Tay. Previously, as an Office Director at DARPA, he led efforts that created operational capabilities in advanced machine learning, crowdsourcing, and big-data analytics, such as the DARPA Network Challenge and Nexus 7. He was formerly the Head of Carnegie Mellon University’s computer science department. As a thought leader, he has spoken and written widely on technology trends and policies, spanning the fields of computing technology, healthcare, and innovation ecosystem. He is a member of the Boards of Directors of the Allen Institute for Artificial Intelligence and the Kaiser Permanente School of Medicine. He served on President’s Commission on Enhancing National Cybersecurity. He has led studies for the National Academies on the impact of federal research investments on economic growth and testified before the US House Science and Technology Committee and the US Senate Commerce Committee.
Alethia Young is the Large Cap Biotech Analyst and Head of Healthcare Research at Cantor Fitzgerald.
Bob Sheehy is co-founder and CEO of Bright Health, and former CEO of UnitedHealthcare. He was also Executive Partner at Flare Capital.
Ana Gupte, Ph.D., is Senior Research Analyst at SVB Leerink covering Healthcare Services, including Managed Care, Healthcare Facilities and Payor Services.
Prior to joining the firm in 2013, Dr. Gupte served as a Vice President and Senior Research Analyst covering Managed Care at Sanford C. Bernstein & Company. Over the course of her career, Dr. Gupte has served in senior roles at Managed Care and Pharmaceutical companies and was a Healthcare Strategy Consultant at McKinsey & Company.
In the 2016 Institutional Investor All-America Research Team rankings, Dr. Gupte achieved a Runner-Up ranking in Healthcare Services encompassing Healthcare Facilities & Managed Care. She has previously been recognized as a Top 3 Analyst in the Institutional Investor 2011 and 2012 All America Research Team and Runner-Up in the 2010 Survey. She was awarded the top stock picker within the FT Thomson StarMine Healthcare Providers and Services in 2012. Dr. Gupte is a frequent contributor on CNBC and Bloomberg TV, as well as print media including the WSJ, NY Times and Forbes.
Dr. Gupte earned a B.S in Chemical Engineering from the Bombay University and a M.S. and Ph.D. in Biomedical Engineering from Pennsylvania State University. She has graduated from the two-year Executive Management program at the Wharton Business School.
Dr. Harrison is a pediatric critical care physician with a proven track record as a top operations executive on a global scale. He is leading Intermountain to embrace bold new approaches focused on improving health while continuing to make healthcare more effective, accessible, and affordable. As a result, Intermountain’s 37,000 employees—who are all called caregivers—continue to re-define value-based care and serve people in new ways.
Dr. Harrison is a national and international thought leader on healthcare transformation and innovation. In 2018, he ranked second among Modern Healthcare’s Most Influential Physician Executives and Leaders. He also tied for second on Modern Healthcare’s list of the 100 Most Influential People in Healthcare.
Two examples of innovations Intermountain is leading:
• Intermountain launched Civica Rx, a not-for-profit generic drug manufacturer and distributor, to make generic medications more available and affordable in hospitals across the nation.
• Intermountain is a founding member of the Utah Alliance for the Determinants of Health, which is a collaboration between numerous community partners designed to proactively address forces that affect people’s health well before they come to a clinic or a hospital, such as chronic hunger, affordable housing, joblessness, personal safety, etc.
Dr. Harrison’s previous healthcare leadership experience has included service as CEO of Cleveland Clinic Abu Dhabi, chief of international business development at Cleveland Clinic, and chief medical operations officer at Cleveland Clinic.
He received his undergraduate degree from Haverford College, his medical degree from Dartmouth Medical School, completed a residency at Intermountain’s Primary Children’s Hospital, and a Master of Medical Management at Carnegie Mellon University.
Dr. Harrison is an all-American triathlete and represented the U.S. at the 2014 World Championships.
Ashish K. Jha, MD, MPH, is a physician, health policy researcher, and the third Dean of the Brown University School of Public Health. Before joining Brown, he was the K.T. Li Professor of Global Health at the Harvard T.H. Chan School of Public Health and Director of the Harvard Global Health Institute (HGHI).
Before joining Lazard, Peter served as Vice Chairman of Corporate and Investment Banking and Chairman of the Financial Strategy and Solutions Group at Citigroup, Inc. He previously served as the Director of the Office of Management and Budget in the Obama Administration and before that as Director of the Congressional Budget Office. Earlier in his career, Peter was the Joseph A. Pechman Senior Fellow and Deputy Director of Economic Studies at the Brookings Institution. During the Clinton Administration, he was a Special Assistant to the President for Economic Policy and before that a staff economist and then Senior Advisor and Senior Economist at the President's Council of Economic Advisers. Orszag has also founded and subsequently sold an economics consulting firm.
Peter graduated summa cum laude in economics from Princeton University and obtained a Ph.D. in economics from the London School of Economics, which he attended as a Marshall Scholar. He has coauthored or coedited a number of books and serves on the Board of Directors of the Peterson Institute for International Economics, Mt. Sinai Medical Center, New Visions for Public Schools, and the Russell Sage Foundation. He is also a member of the National Academy of Medicine.
John Rogers is a Professor of Materials Science and Engineering, Biomedical Engineering and Medicine at Northwestern University.
Rogers' research seeks to understand and exploit interesting characteristics of 'soft' materials, such as polymers, liquid crystals, and biological tissues as well as hybrid combinations of them with unusual classes of micro/nanomaterials, in the form of ribbons, wires, membranes, tubes or related. The aim is to control and induce novel electronic and photonic responses in these materials; and also develop new 'soft lithographic' and biomimetic approaches for patterning them and guiding their growth. This work combines fundamental studies with forward-looking engineering efforts in a way that promotes positive feedback between the two. Current research focuses on soft materials for conformal electronics, nanophotonic structures, microfluidic devices, and microelectromechanical systems, all lately with an emphasis on bio-inspired and bio-integrated technologies. These efforts are highly multidisciplinary, and combine expertise from nearly every traditional field of technical study.
Professor Rogers has invented over 80 patents and patent applications, more than 50 of which are licensed or in active use by large companies and startups that he has co-founded, including Active Impulse Systems, Semprius, MC10, CoolEdge, XCeleprint and Transient Electronics.
His education includes:
Ph.D. in Physical Chemistry, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts
S.M. in Physics, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts
S.M. in Chemistry, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts
B.S. in Physics, University of Texas, Austin, Austin, TX
B.A. in Chemistry, University of Texas, Austin, Austin, TX
Andy is a general partner at Town Hall and brings decades of private and public sector leadership in health care, business and technology. Over his career, Andy has been a part of many of the most significant and successful initiatives in health care impacting millions of Americans and the shape of the health care system. Andy previously served as the Acting Administrator of the Center for Medicare and Medicaid Services (CMS) under President Obama. He spent a decade at Optum, an organization he helped lead from before its formal inception to the time where it exceeded $35 billion in revenue. In the 1990s, Andy was the founder and CEO of HealthAllies, a digital health company that served the un- and under-insured.
Andy is currently Board Chair of United States of Care, a national non-profit health advocacy organization he founded. Andy leads a number of national health care initiatives, including one on the future of health care, which he co-chairs at the Bipartisan Policy Center. Today he is a highly recognizable voice in health care, with a regular column in the USA Today and regular appearances on CNN, MSNBC and Fox. He is listed in the Politico 50 (right after Bob Mueller and right before Charles Kessler) and was recognized by Modern Healthcare as one of the 10 most influential people in health care.
Andy graduated from the College of Arts and Sciences and the Wharton School at the University of Pennsylvania and holds an MBA from the Harvard Business School. He was recently named a Distinguished Policy Fellow at the University of Pennsylvania. He lives in Minneapolis and on Twitter with his wife Lana and their two sons, Caleb, currently in college, and Zach, currently in high school, both of whom are fans of all things basketball and are active participants in conversations about world events with their parents.
Tim Wentworth leads Express Scripts and Cigna Services. In this role, Wentworth oversees the Express Scripts business as well as independent services, including eviCore.
Wentworth formerly served as President and Chief Executive Officer of Express Scripts, where he was responsible for all aspects of the company’s strategic direction and core business. He joined Express Scripts when the company merged with Medco in April 2012. At Medco, he led the employer and key accounts organizations for nearly 14 years. He also served as President and CEO of Accredo, the company's specialty pharmacy.
Wentworth earned a bachelor's degree in industrial and labor relations from Cornell University and an associate's degree in business from Monroe Community College.
Ali J. Satvat (Menlo Park) joined KKR in 2012 and is a Member of KKR on the Health Care industry team within KKR’s Americas Private Equity platform. Mr. Satvat leads KKR’s Health Care Strategic Growth investing efforts and sits on the Health Care Strategic Growth Investment Committee and the Health Care Strategic Growth Portfolio Management Committee. Mr. Satvat currently serves on the boards of directors of AcuFocus, Arbor Pharmaceuticals, Blue Sprig Pediatrics, BridgeBio Pharma, Clarify Health Solutions, Coherus BioSciences, Eidos Therapeutics, Falcon Vision, Headlands Research, Impel NeuroPharma, Slayback Pharma and Trilogy MedWaste and has also been involved in KKR’s investments in Ajax Health, GenesisCare, Gland Pharma, Panasonic Healthcare, PRA Health Sciences and Spirox. Prior to joining KKR, Mr. Satvat was a principal with Apax Partners, where he invested in health care and was actively involved with many of the firm’s successful private equity and growth equity investments. Previously, Mr. Satvat held various positions with Johnson & Johnson Development Corporation, Audax Group and The Blackstone Group. Mr. Satvat holds an A.B., magna cum laude, in History and Science from Harvard College and an M.B.A. in Health Care Management and Entrepreneurial Management from the Wharton School of the University of Pennsylvania. Mr. Satvat is a member of the board of directors of the Healthcare Private Equity Association.
Jeff Borghoff was diagnosed with younger onset / early-stage Alzheimer's disease in 2016 at the age of 51. A former IT professional, Jeff is now leading a charge against Alzheimer's disease. Since his diagnoses, he has served as a member of the Alzheimer's Association's national Early Stage Advisor Group. Currently he is serving as an Alzheimer's Impact Movement congressional team member, a member of the Alzheimer’s Association of Greater NJ Chapter's board of directors, and a sub-committee member to the National Institute on Aging (NIA). Jeff and his family are featured in the forthcoming public television documentary film 'SPENT - The Hidden Cost of Dementia'. Jeff was also a participant in Biogen’s failed clinical trial for Alzheimer’s.
Dr. Roozbeh Ghaffari is a biomedical engineer, inventor, professor and entrepreneur. Dr. Ghaffari co-founded wearable health technology startup MC10 and led the development and launch of the BioStamp and My UV Patch wearable products. His contributions in soft bioelectronics, nanoscale sensors, microfluidics and neuroscience have been recognized with the MIT100K Grand Prize, the Harvard Business School Social Enterprise Grand Prize, TEDx Gateway invited talk, and the MIT Technology Review Magazine's Top 35 Innovators Under 35. He has published over 80 academic papers and is inventor on over 30 patents. Dr. Ghaffari joined the Center for Bio-Integrated Electronics at Northwestern University in 2017, where he is the director of translational research and research associate professor in the Department of Biomedical Engineering. In 2017, Dr. Ghaffari co-founded Epicore Biosystems to commercialize a new class of ‘skin-like’ wearable microfluidic devices. Dr. Ghaffari graduated from MIT with BS and MEng degrees in Electrical Engineering and received his PhD in biomedical engineering from the Harvard-MIT Division of Health Sciences and Technology.
As Collective Health’s Co-Founder and Chief Health Officer, Dr. Rajaie Batniji oversees partnerships with healthcare networks and providers, analytics and research, and Collective Health’s employee health management programs. Collective Health brings together Dr. Batniji’s academic and professional careers as both a physician and as a political economist, and his aspiration to create a better and more efficient health insurance experience.
Dr. Batniji is also a Clinical Assistant Professor of Medicine at the Stanford University School of Medicine, where he previously trained in Internal Medicine. He received a DPhil in International Relations (Political Economy) from Oxford University, where he was a Marshall Scholar, an MD from UCSF, and BA and MA degrees from Stanford University.
Ed Ellison, MD, serves as Executive Medical Director/Chairman of the Board, Southern California Permanente Medical Group (SCPMG); Chairman of the Board and CEO, The Southeast Permanente Medical Group. He also is Co-CEO of The Permanente Federation, LLC, a consortium of all the Permanente Medical Groups in the nation, supporting the work of more than 22,000 Kaiser Permanente physicians in the eight Kaiser Permanente regions across the country.Dr. Ellison joined SCPMG in 1984 as a family medicine physician and has served in multiple roles with the organization. In 2002, Dr. Ellison was appointed area medical director for Orange County and joined SCPMG’s Board of Directors. He is a past recipient of Orange County’s Family Medicine Physician of the Year. After completing his undergraduate degree at Duke University, Dr. Ellison received his medical degree from the University of Virginia. He completed his residency training in Family Medicine at Halifax Hospital Medical Center, University of South Florida, where he served as chief resident. Dr. Ellison is board certified in Family Medicine and is a diplomate of the American Academy of Family Physicians. He has attended the Advanced Leadership Program at the University of North Carolina at Chapel Hill and Harvard’s Advanced Management Program.
William B. Hurlbut is a physician and Adjunct Professor in the Department of Neurobiology at Stanford University Medical Center. His primary areas of interest involve the ethical issues associated with advancing biomedical technology, the biological basis of moral awareness, and studies in the integration of theology and philosophy of biology. In addition to teaching at Stanford, he has worked with NASA on projects in astrobiology and as a member of the Chemical and Biological Warfare working group at Stanford’s Center for International Security and Cooperation. He has organized and co-chaired three multi-year interdisciplinary faculty projects at Stanford University, “Becoming Human: The Evolutionary Origins of Spiritual, Religious and Moral Awareness,” “Brain Mind and Emergence,” and the ongoing “The Boundaries of Humanity: Human, Animals, and Machines in the Age of Biotechnology.” In addition, he is Co-leader, together with U.C. Berkeley professor Jennifer Doudna of a new initiative entitled “The challenge and opportunity of gene editing: a project for reflection, deliberation and education. ”From 2002-2009 Dr. Hurlbut served on the President's Council on Bioethics.
Paul Dabrowski is CEO of Synthego. He founded the company with his brother, Michael Dabrowski, and together they developed the company’s world-class commercial offering for genome engineering. Before Synthego, Paul was the lead digital designer for the Falcon 9 rocket and Dragon spacecraft at SpaceX. He also founded a mobile software company and designed a portable electron microscope for DNA sequencing. Paul was born in Illinois to Polish immigrants and earned his MS/BS in Computer Engineering from the University of Illinois at Urbana-Champaign.
David Nixon is Chief Executive Officer of InformedDNA.
8:00am - 9:00am
9:00am - 12:30pm
A Sitdown with Former FDA Commissioner Dr. Scott Gottlieb
A conversation with one of the most influential FDA commissioners ever, about the broad policy initiatives he developed and implemented and what lies ahead for the pharmaceutical industry.
Dr. Scott Gottlieb, Resident Fellow, American Enterprise Institute; Contributor, CNBC; Fmr Commissioner, FDA
Interviewer: Meg Tirrell, Biotech and Pharma Reporter, CNBC
(Re)Focusing Big Pharma
Dr. Vasant Narasimhan, CEO of the Swiss-based pharma giant Novartis, talks innovation, new pricing models and new product pipelines, all at scale.
Dr. Vasant (Vas) Narasimhan, CEO, Novartis
Interviewer: Jim Cramer, “Mad Money w/ Jim Cramer;” Host & Co-Anchor “Squawk on the Street,” CNBC
New Models: DIY Generics
Faced with ever-rising prices for oft-used generic drugs, one provider decided to make its own. We check in on the progress of Civica Rx with one of its founders.
Presentation: Dr. Marc Harrison, President and CEO, Intermountain Healthcare
The Provider View: Heal Thyself
The number of doctor suicides in the United States is more than twice that of the general population. As the leader of one of the largest medical groups in the world, Dr. Ed Ellison is developing new ways to address the medical mental health crisis.
Presentation: Dr. Ed Ellison, Executive Medical Director/Chairman, Southern California Permanente Medical Group; Chairman and CEO, Southeast Permanente Medical Group; Co-CEO and Executive Medical Director, The Permanente Federation
New Combinations
When Cigna closed its $54 billion deal in December to buy Express Scripts, it created one of the biggest providers of pharmacy benefits and insurance plans in the United States. Its purpose: to contain costs for employers and to leverage data to create more integrated care for consumers. We ask, how is it going so far?
David Cordani, President and CEO, Cigna
Tim Wentworth, President, Express Scripts and Cigna Services; Fmr CEO, Express Scripts
Interviewer: Bertha Coombs, Reporter, CNBC
The Catalyst: Creating Innovation in Health Care
There are few, if any, more innovative, more daring, and more iconic health care executives. We’ll hear about the process that drives groundbreaking invention, and her dream of permanently alleviating the shortage of transplantable organs.
Martine Rothblatt, Founder and CEO, United Therapeutics; Founder and Fmr CEO, Sirius Satellite Radio
Presentation followed by Q & A with Melissa Lee, “Fast Money” Host and “Power Lunch” Co-anchor, CNBC
Live Demonstration: Sweating, the Details
How, and what, you sweat can tell a lot about your overall wellness.
Northwestern University professor John Rogers will reveal how his wearable microfluidic sweat analytics system measures sweat and sweat biomarkers accurately and in real time so athletes, fitness pros and others can keep hydrated and stay healthy.
Dr. John Rogers, Biomedical Engineering and Neurological Surgery Professor, Northwestern University McCormick School of Engineering
Interviewer: Christina Farr, Technology and Health Reporter, CNBC.com
12:30pm - 1:45pm
1:45pm - 5:00pm
New Models: Reinventing the Clinical Trial
Alphabet’s healthcare and life sciences arm is using data and machine learning to try and reinvent the famously difficult and inefficient clinical trial process.
Scarlet Shore, Head of Product and Project Baseline platform lead, Verily
What’s Next: Deals and IPOs
What companies are candidates for acquisition? Which unicorns will go public? Where will private money flow? Let’s find out.
Peter Orszag, CEO Financial Advisory and Fmr Global Co-Head of Health Care, Lazard Ltd
Jorge Conde, General Partner, Andreessen Horowitz
Ali Satvat, Private Equity Member, KKR
Moderator: David Faber, “Squawk on the Street” Co-anchor, CNBC
Genetics, CRISPR and Medical Ethics
Genomic medicine’s progress and future potential is hugely exciting, but it comes with enormous ethical implications. So how can we ensure its responsible use?
Paul Dabrowski, CEO, Synthego
Dr. William Hurlbut, Adjunct Professor, Senior Research Scholar in Neurobiology, Stanford Medical School; Distinguished Fellow, The Center for Bioethics and Human Dignity
Dr. Samarth Kulkarni, CEO, CRISPR Therapeutics
Moderator: Meg Tirrell, Biotech and pharma reporter, CNBC
Transformation: Data, A.I. and Health Care
The global health care market is among the AI industry’s fastest-growing subsectors. Find out how companies in this space are using big data analysis and AI to reinvent drug development, diagnostics and delivery.
Daphne Koller, Founder and CEO, insitro
Peter Lee, Corporate Vice President, Microsoft Healthcare
Dr. Jennifer Schneider, President, Livongo
James Park, Co-founder President and CEO, Fitbit
Moderator: Christina Farr, Technology and Health Reporter, CNBC.com
The Patient View: Courage and Purpose
When Biogen and its partner Eisai announced they were halting their clinical trial for Alzheimer’s, Jeff Borghoff, a patient in the failed drug trial, was devastated. But he isn’t giving up. Determined to find a treatment, he is exploring other possibilities. Here he shares important insights on the patient experience.
Presentation: Jeff Borghoff, Software Designer and Biogen Alzheimer’s Trial Participant
Interviewer: Sharon Epperson, Senior personal finance correspondent, CNBC
Defining the Future of US Health Care
Groundbreaking technology, backbreaking costs, policy battles, incredible cures. A panel of leading health care influencers discuss what they see coming next.
Dr. Ashish Jha, Global Health Initiative Director, Harvard T.H. Chan School of Public Health
Bob Sheehy, Co-founder and CEO, Bright Health; Fmr CEO, UnitedHealthcare
Andy Slavitt, General Partner, Town Hall Ventures; Fmr Commissioner, Centers for Medicare and Medicaid Services
Moderator: Bertha Coombs, Reporter, CNBC
The View from New Brunswick
Johnson & Johnson is continuously pioneering new techniques and concepts for a brighter, healthier future. What the landscape looks like from atop one of the world’s biggest and most admired health care companies.
Alex Gorsky, Chairman and CEO, Johnson & Johnson
Interviewer: Meg Tirrell, Biotech and pharma reporter, CNBC
5:00pm - 6:00pm
Continue to visit us to learn about upcoming CNBC Events. Please email healthyreturns@cnbc.com with any questions, and subscribe to our weekly newsletter with the latest.
HSS is the world’s leading academic medical center dedicated to musculoskeletal health, powered by Hospital for Special Surgery – ranked #1 in the nation for Orthopedics for the past eleven years in a row by U.S. News & World Report. HSS helps some of the nation’s largest and highest-performing corporations with population-scale support to improve workforce wellness and performance.
Learn more at HSS.edu/EmployerConnect.
A limited number of guestrooms have been reserved for Healthy Returns attendees at the reduced room rate of $309/night (+taxes and fees). A deposit of first night’s room and tax will be charged at the time of booking. Deposits are refundable up to 72 hours prior to arrival.
To book please contact Hilton Reservations at 212-586-7000 and request the Healthy Returns rate or book online here.
